Myositis

Comparative, Double-Blind, Investigational Study Evaluating the Efficacy and Safety of Abatacept SC with Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults with Active Idiopathic Inflammatory Myopathy (IIM)

  • You Must:
    • Be diagnosed of definite or probable IIM
    • Demonstrate muscle weakness
    • Have active disease despite adequate prior treatment experience with corticosteroids, immunosuppressants, or biologic medications
  • You Must Not:
    • Have Inclusion Body Myositis or myositis other than IIM
    • Have been treated with rituximab in the past year or any other biologic treatment or IVIG in the past 6 months

 

  • This is a 52 week long investigational study – Visits occur at Screening, Baseline, and about every 4 weeks afterwards
  • For more information, please contact (610) 868-1336 ext. 112